Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 13 points (-0.1%) at 18,461 as of Wednesday, July 27, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,210 issues advancing vs. 1,692 declining with 152 unchanged.

The Drugs industry currently sits up 1.9% versus the S&P 500, which is down 0.3%. Top gainers within the industry include

Seattle Genetics

(

SGEN

), up 6.5%,

Celgene

(

CELG

), up 2.0%,

GlaxoSmithKline

(

GSK

), up 1.6%,

Allergan

(

AGN

), up 1.3% and

Vertex Pharmaceuticals

(

VRTX

), up 1.2%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Novo Nordisk A/S

(

NVO

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Novo Nordisk A/S is down $0.39 (-0.7%) to $55.90 on average volume. Thus far, 676,115 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $55.83-$56.15 after having opened the day at $55.84 as compared to the previous trading day's close of $56.29.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $143.8 billion and is part of the health care sector. Shares are down 3.1% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Novo Nordisk A/S

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Novo Nordisk A/S Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Novartis

(

NVS

) is down $0.62 (-0.8%) to $82.40 on light volume. Thus far, 649,133 shares of Novartis exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $82.28-$82.65 after having opened the day at $82.37 as compared to the previous trading day's close of $83.02.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. Novartis has a market cap of $198.7 billion and is part of the health care sector. Shares are down 3.5% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Novartis a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Novartis

as a

buy

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Novartis Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Abbott Laboratories

(

ABT

) is down $0.22 (-0.5%) to $43.38 on light volume. Thus far, 3.7 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 10.9 million shares. The stock has ranged in price between $43.31-$43.62 after having opened the day at $43.57 as compared to the previous trading day's close of $43.60.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abbott Laboratories manufactures and sells health care products worldwide. Abbott Laboratories has a market cap of $63.8 billion and is part of the health care sector. Shares are down 2.9% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Abbott Laboratories

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and a generally disappointing performance in the stock itself. Get the full

Abbott Laboratories Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).